Women's health care company Organon announced this week that it has signed an exclusive distribution and promotion agreement for Eli Lilly's migraine medicines, Emgality and Rayvow, in Europe.
The deal, which includes a $50 million upfront payment and sales-based milestones, is expected to close in the first quarter of 2024.
Under the agreement, Organon will exclusively distribute and promote the two drugs in Europe, while Lilly retains marketing authorization and manufacturing responsibilities.
Emgality, a monoclonal antibody, received EMA and FDA approval in 2018 for the preventive treatment of migraine in adults. Rayvow, an oral 5-HT1F receptor agonist, was approved by the FDA in 2019.
